Skye Bioscience Reports Second Quarter 2025 Financial Results and Business Update
Provided By GlobeNewswire
Last update: Aug 7, 2025
SAN DIEGO, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ: SKYE) (“Skye” or the “Company”), a clinical stage biotechnology company developing next-generation molecules that modulate G-protein-coupled receptors to treat obesity, overweight, and related conditions, today reported financial results for the second quarter ended June 30, 2025, along with key accomplishments and upcoming milestones.
Read more at globenewswire.com
